Peptifact

Gattex Cost: About $1,484 a Vial, $52,000 a Medicare Claim, No Generic — What the Public Records Show

What Gattex (teduglutide) costs, from public government data read on 19 November 2026: Medicaid paid an average of $1,483.56 per 5 mg vial in 2024 (about $44,500 for 30), Medicare Part D spent $383,837 per patient in 2025 and $52,096 a claim in early 2026, no generic is approved, it is not on any Medicare negotiation list, and the manufacturer's co-pay programme is for commercially insured patients only.

Robert F · Edited by Caroline S · Published 2026-11-19

Illustration: An open insulated shipping box with cold packs and a clear glass vial of white powder on a white surface.
Illustration

Gattex (teduglutide) is a once-daily injection for adults and children aged 1 and over with short bowel syndrome who depend on intravenous nutrition or fluids. It comes as 5 mg single-dose vials, dispensed in 30-vial kits, so its cost is a price per vial multiplied by 30 a month or 365 a year.

There is no public pharmacy price for it. Gattex is not in Medicaid's national price survey, and the manufacturer's site sends patients to a support programme and specialty pharmacies rather than publishing a figure. What remains are the government's own spending files, which show what Medicaid and Medicare actually paid. What teduglutide is and how it acts on the gut is on Peptide Lexicon's teduglutide entry; its place among approved peptide drugs is in our FDA-approved peptides census.

The figures, side by side

Benchmark Per vial 30 vials Per year Source and date
Medicaid average paid, 2024 $1,483.56 $44,507 $541,498 at 365 vials CMS Medicaid Spending by Drug, 2024
Medicaid average per claim, 2024 — $45,679 per claim — Same
Medicare average per claim, 2025 — $51,637 per claim — CMS Quarterly Part D Spending by Drug
Medicare average per patient, 2025 — — $383,837 Same
Medicare average per claim, Q1 2026 — $52,096 per claim — Same, first quarter 2026
Manufacturer co-pay programme — as little as $0 per prescription — gattex.com, read 19 Nov 2026 (commercial insurance only)

The 30-vial and yearly Medicaid figures are our multiplication. Every government figure is gross: Medicaid and Medicare both receive manufacturer rebates, which are confidential and not published per drug. A Medicare patient's yearly figure is lower than 365 vials would imply, because not every patient is treated for the whole year.

What Medicaid paid per vial

CMS's Medicaid Spending by Drug file counts "dosage units". For Gattex in 2024 it reports 151,705 units across 4,927 claims, which is 30.8 units per claim. Since the product is dispensed as a 30-vial kit, a unit reads as one vial.

Year Medicaid spending Units Claims Paid per unit Per claim
2020 $88.3 million 62,701 2,117 $1,408.56 $41,719
2021 $120.3 million 81,858 2,770 $1,469.52 $43,427
2022 $148.4 million 100,419 3,407 $1,477.71 $43,554
2023 $182.4 million 123,951 4,004 $1,471.19 $45,543
2024 $225.1 million 151,705 4,927 $1,483.56 $45,679

The striking line is not the price. Over five years the amount paid per unit rose 5.3%, while Medicaid's total spending on Gattex grew 2.5-fold and its claims 2.3-fold. Almost all of the growth is more prescriptions, not a higher price per vial. The file does not say why; children aged 1 and over were added to the label in 2019, and Medicaid covers many children, but the file does not split claims by age, so that link is not established here.

What Medicare spends

Year Part D spending Claims People Per claim Per person
2020 $297.3 million 6,558 847 $45,340 $351,051
2021 $294.3 million 6,191 827 $47,538 $355,871
2022 $297.1 million 6,071 851 $48,944 $349,164
2023 $330.4 million 6,504 914 $50,800 $361,490
2024 $357.6 million 7,085 962 $50,478 $371,761
2025 $391.5 million 7,582 1,020 $51,637 $383,837
Q1 2026 $95.6 million 1,836 797 $52,096 —

Part D spending passed $390 million in 2025 for about a thousand people. Spending per claim rose 2.3% from 2024 to 2025 and a further 0.9% in the first quarter of 2026 against the 2025 average. A Part D claim can cover more than 30 days, so a per-claim figure is not a monthly price.

No generic, and no negotiated Medicare price

Drugs@FDA (data updated 17 November 2026) lists one teduglutide application: NDA 203441, Takeda, approved on 21 December 2012 as a new molecular entity, prescription status. There is no generic approval. FDA's drug-listing directory, read the same day, holds Gattex as the only finished teduglutide product — the 30-vial carton (NDC 68875-0101-2), the assembled 30-vial kit and the one-vial kit — plus six listings of teduglutide as bulk ingredient, from Biocon, MSN Life Sciences, PolyPeptide Laboratories, Olon, Shanghai AmbioPharm and Boehringer Ingelheim RCV, and two Patheon listings of vials for further processing. A bulk-ingredient listing is raw material for manufacturing; it is not an approval to sell a product.

Gattex is not on CMS's lists of drugs selected for negotiation for 2026, 2027 or 2028, nor on the top 50 negotiation-eligible drugs for 2028 that CMS published with the third cycle. CMS's published selection steps exclude "certain orphan drugs", low-spend drugs and plasma-derived products. CMS does not publish why any single drug was left out, so this page does not say which step applied to Gattex.

Where the money in the vial goes

The label sets the dose by weight, 0.05 mg/kg once a day (0.025 mg/kg with moderate or severe kidney impairment). Each vial holds 5 mg, but the label states that at most 0.38 mL, containing 3.8 mg, can be withdrawn, and the rest is discarded. So a vial covers a full daily dose up to 76 kg of body weight (3.8 ÷ 0.05, our arithmetic), and a lighter patient uses less of it while the cost per vial stays the same.

At Medicaid's 2024 average of $1,483.56 a vial, that is $390 per milligram withdrawn at the 3.8 mg ceiling, and $495 per milligram for a 60 kg adult whose dose is 3.0 mg. These are our calculations from public figures, to show that a child or a smaller adult pays the full vial price; they are not a price anyone is quoted. The label sections we read do not describe dosing above 76 kg.

The co-pay programme

gattex.com, read on 19 November 2026, states that eligible patients "may pay as little as $0 per GATTEX prescription", subject to eligibility and terms. Its footnote sets two conditions: enrollment in Takeda Patient Support, and commercial insurance. The page does not publish a yearly maximum or the full terms; it refers patients to Takeda Patient Support (1-866-888-0660). People on Medicare or Medicaid are, by that condition, outside the programme. The site describes specialty-pharmacy dispensing coordinated by a support specialist.

What these figures do not tell anyone

  • A cash price. No public source lists one; the government figures are what programmes paid, before rebates.
  • A patient's own share. That depends on the plan; the Part D out-of-pocket cap and the co-pay programme's terms set it, not the gross figures above.
  • Whether the price per vial has changed in 2026. The newest per-unit Medicaid figure is for 2024; the Medicare per-claim figure for early 2026 is the most recent signal.
  • Whether Gattex is the right treatment. Who should take it, at what dose and with which pre-treatment tests (the label requires colonoscopy in adults within six months before starting) is for the treating gastroenterology team.

Per claim, Gattex costs far more than the other approved peptide drugs on our cost pages. Prices for the other approved peptides we have surveyed are on our Linzess cost, Trulance cost and Tymlos and Forteo cost pages; the wider market is on how much do peptides cost.

Sources

  • CMS, Medicaid Spending by Drug, 2020–2024 (data.cms.gov, modified 25 June 2026), Gattex rows; read 19 November 2026.
  • CMS, Medicare Part D Spending by Drug, 2020–2024 (data.cms.gov, modified 25 June 2026), and Medicare Quarterly Part D Spending by Drug, 2025 and 2026 Q1 (modified 23 July 2026), Gattex rows; read 19 November 2026.
  • Medicaid NADAC 2023, 2024, 2025 and 2026 datasets, data.medicaid.gov API, searched for "GATTEX" and "TEDUGLUTIDE" (0 rows each; control: Trulance 3 mg, 52 rows in 2023 and 2024); read 19 November 2026.
  • Drug Products in the Medicaid Drug Rebate Program, data.medicaid.gov (modified 9 November 2026): Gattex NDCs listed by Takeda through 2026 Q3; read 19 November 2026.
  • Drugs@FDA via openFDA (NDA 203441, 19 submissions), data updated 17 November 2026; openFDA NDC directory, query generic_name:teduglutide; Gattex prescribing information via openFDA labels (effective 5 September 2025); all read 19 November 2026.
  • CMS, Selected Drugs and Negotiated Prices page; fact sheets on the selected drug lists for 2026, 2027 and 2028 and on the top 50 negotiation-eligible drugs for 2028; read 19 November 2026.
  • gattex.com home page and "Insurance and Financial Support" page, rendered in a headless browser; read 19 November 2026.

Frequently asked questions

How much does Gattex cost?

There is no published retail price we could read. The clearest public figure is what Medicaid paid: an average of $1,483.56 per 5 mg vial in 2024, which is about $44,500 for a 30-vial kit and about $541,000 for a year of one vial a day, before the confidential rebates Medicaid receives. Medicare Part D spent $383,837 per patient in 2025 before rebates.

Is there a generic Gattex?

No. On 19 November 2026 Drugs@FDA listed only Takeda's original application for teduglutide (NDA 203441, approved 21 December 2012) and no generic approval. FDA's drug-listing directory held eight registrations of teduglutide as bulk ingredient or material for further processing, which are raw materials, not a product a pharmacy can dispense.

Does Medicare cover Gattex?

Medicare Part D paid for it: $391.5 million across 7,582 claims for 1,020 people in 2025. What a member pays depends on the plan's tier and the Part D out-of-pocket cap; Gattex has no negotiated Medicare price, because it was not selected for 2026, 2027 or 2028. The manufacturer's co-pay programme requires commercial insurance.

What is the Gattex co-pay card?

The Takeda Patient Support Co-Pay Assistance Program. gattex.com, read on 19 November 2026, states that eligible patients 'may pay as little as $0' per prescription, that enrollment in Takeda Patient Support and commercial insurance are required, and that other terms apply. The page does not publish a yearly maximum.

Why is Gattex not in the NADAC price survey?

NADAC surveys what retail community pharmacies pay wholesalers. Gattex is supplied through specialty pharmacies, and no Gattex or teduglutide row appears in any NADAC file from 2023 to 2026. The Medicaid and Medicare spending files are therefore the only public per-unit and per-claim figures.